目前前列腺癌特异性抗原检测法（PSA）的益处是否大于伤害，研究者们并不清楚，但是近日，刊登在国际杂志Journal of Clinical Oncology上的一项研究报告指出，长寿的男性或许可以从PSA检测法中获得益处。
来自纽约Memorial Sloan-Kettering的研究者Ethan Basch博士进行了PSA检测法在男性前列腺癌中的实验研究。研究人员发现，基于随机比对临床试验，PSA测试法可以降低前列腺癌死亡率，但是研究者并不清楚其所带来的益处是否超过筛查所引发的害处。证据显示，长寿的男性可以从PSA测试法中获得益处，对于大多数男性来说，前列腺活组织检查相关的负面事件比较低，但是可以增加其感染的比率，
研究者表示，因为证据并不能清楚揭示PSA筛查的问题，因此对于PSA筛查所引发的益处是否大于害处目前并不清楚，不过未来研究者们希望通过深入研究确定其具体的利弊。（生物谷Bioon.com）
编译自：Benefits of prostate-specific antigen testing remain unclear
doi:10.1200/JCO.2012.43.3441
PMC:
PMID:
Screening for Prostate Cancer With Prostate-Specific Antigen Testing: American Society of Clinical Oncology Provisional Clinical Opinion
Ethan Basch, Thomas K. Oliver, Andrew Vickers, Ian Thompson, Philip Kantoff, Howard Parnes, D. Andrew Loblaw, Bruce Roth, James Williams and Robert K. Nam⇓
Purpose An American Society of Clinical Oncology (ASCO) provisional clinical opinion (PCO) offers timely clinical direction to the ASCO membership after publication or presentation of potentially practice-changing data from major studies. This PCO addresses the role of prostate-specific antigen (PSA) testing in the screening of men for prostate cancer. Clinical Context Prostate cancer is the second leading cause of cancer deaths among men in the United States. The rationale for screening men for prostate cancer is the potential to reduce the risk of death through early detection. Recent Data Evidence from a 2011 Agency for Healthcare Research and Quality systematic review primarily informs this PCO on the benefits and harms of PSA-based screening. An update search was conducted to March 16, 2012, for additional evidence related to the topic. Results In one randomized trial, PSA testing in men who would not otherwise have been screened resulted in reduced death rates from prostate cancer, but it is uncertain whether the size of the effect was worth the harms associated with screening and subsequent unnecessary treatment. Although there are limitations to the existing data, there is evidence to suggest that men with longer life expectancy may benefit from PSA testing. Adverse events associated with prostate biopsy are low for the majority of men; however, several population-based studies have shown increasing rates of infectious complications after prostate biopsy, which is a concern
